InvestorsHub Logo
Followers 22
Posts 1379
Boards Moderated 0
Alias Born 03/31/2017

Re: None

Sunday, 02/21/2021 8:40:45 AM

Sunday, February 21, 2021 8:40:45 AM

Post# of 403568

The Company is collaborating with a Regional Biocontainment Laboratory (RBL) for federal grants to fund continued research on Brilacidin as a treatment for SARS-CoV2. An earlier grant application was unsuccessful. At the time of that grant filing deadline, the only research data available was limited to non-human Vero cells. Subsequent to the filing, human cell line experiments were completed and the data is now available. Additional grant applications incorporating the new data are planned for submission before the end of 2020.



2020-11-16 10Q

http://www.edgarmaster.com/Inet/main/DataFeedHtml1.jsp

Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track Designation

FDA Grants IND Approval for Phase 2 Clinical Trial of Innovation Pharmaceuticals - Brilacidin for Treating
COVID-19

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News